Author(s): Shah NP, Kantarjian HM, Kim DW, Ra D, DorlhiacLlacer PE,
Abstract Share this page
Abstract PURPOSE: Dasatinib is a BCR-ABL inhibitor, 325-fold more potent than imatinib against unmutated BCR-ABL in vitro. Phase II studies have demonstrated efficacy and safety with dasatinib 70 mg twice daily in chronic-phase (CP) chronic myelogenous leukemia (CML) after imatinib treatment failure. In phase I, responses occurred with once-daily administration despite only intermittent BCR-ABL inhibition. Once-daily treatment resulted in less toxicity, suggesting that toxicity results from continuous inhibition of unintended targets. Here, a dose- and schedule-optimization study is reported. PATIENTS AND METHODS: In this open-label phase III trial, 670 patients with imatinib-resistant or -intolerant CP-CML were randomly assigned 1:1:1:1 between four dasatinib treatment groups: 100 mg once daily, 50 mg twice daily, 140 mg once daily, or 70 mg twice daily. RESULTS: With minimum follow-up of 6 months (median treatment duration, 8 months; range, < 1 to 15 months), marked and comparable hematologic (complete, 86\% to 92\%) and cytogenetic (major, 54\% to 59\%; complete, 41\% to 45\%) response rates were observed across the four groups. Time to and duration of cytogenetic response were similar, as was progression-free survival (8\% to 11\% of patients experienced disease progression or died). Compared with the approved 70-mg twice-daily regimen, dasatinib 100 mg once daily resulted in significantly lower rates of pleural effusion (all grades, 7\% v 16\%; P = .024) and grade 3 to 4 thrombocytopenia (22\% v 37\%; P = .004), and fewer patients required dose interruption (51\% v 68\%), reduction (30\% v 55\%), or discontinuation (16\% v 23\%). CONCLUSION: Dasatinib 100 mg once daily retains the efficacy of 70 mg twice daily with less toxicity. Intermittent target inhibition with tyrosine kinase inhibitors may preserve efficacy and reduce adverse events. TRIAL REGISTRATION: ClinicalTrials.gov NCT00123474.
This article was published in J Clin Oncol
and referenced in Journal of Leukemia